DNAVISION IS THE FIRST EUROPEAN PHARMACOGENOMIC SERVICE LABORATORY TO SUCCEED ISO/IEC 17025 AUDIT

Brussels, September 2005 – DNAVision laboratory, a BioVallée spin-off, announced today that it has succeeded an official audit under ISO Standard 17025. DNAVision will be the first full-service pharmacogenetic / pharmacogenomic DNA testing laboratory to receive this accreditation in Europe.
ISO 17025 is an international standard that assesses the technical competency of analytical laboratories and helps to ensure accurate data generation, controlled test methods and procedures, and properly trained personnel. ISO 17025 covers every aspect of laboratory management, including sample preparation, analytical testing proficiency, report generation and record keeping.
“DNAVision is proud to be the first full-service private European pharmacogenomic DNA testing laboratory to reach this globally-recognized accreditation. We are now in a new era where pharmacogenomic analytical data needs the highest quality requirements” said Jean-Pol Detiffe, business director of DNAVision laboratory. “Our success in meeting the stringent standards for this ISO designation reflects our ongoing efforts to ensure unsurpassed consistency in our procedures and the accuracy of our results.”
Our accreditation scope includes different analytical methods:
- expression profiling using Affymetrix (first laboratory in the world)
- SNP genotyping (first laboratory in Europe)
- DNA sequencing
- other tests in the field of food quality, animal diagnostic, …

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services.
DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment. DNAVision is a spin-off of BioVallée, University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be